Lota S. Zoth

CIK 1278219 · CHIEF SCIENTIFIC OFFICER · last filed 2026-06-17

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$87.9K

Companies

11

Total Filings

66

Lifetime Open-Market Net

-$84.0K

Filer Profile

Reported Address
334 CR 692
BUFFALO GAP, TX 79508
Formerly Known As
ZOTH LOTA S (2004–2007)
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ENGNW Director $0.23 $0 4 2026-06-17
INO Director 8,726 $1.25 $10.9K -$37.8K 15 2026-05-21
FFIN Director 2,142 $33.16 $71.0K $0 1 2026-05-05
89bio, Inc. (ETNB) Delisted Director $14.84 $0 7 2025-10-30
LUMOS PHARMA, INC. (LUMO) Delisted Director 0 $4.34 $0 $0 6 2024-12-13
ZYME Director $26.24 $0 4 2022-12-23
LUMOS PHARMA, INC. (NLNK) Delisted Director 1,112 $0 11 2020-01-06
Spark Therapeutics, Inc. (ONCE) Delisted CHIEF SCIENTIFIC OFFICER 0 $0 6 2019-12-17
Orexigen Therapeutics, Inc. (OREX) Delisted Director $0 6 2017-07-18
HYPERION THERAPEUTICS INC (HPTX) Delisted Director 0 $0 2 2015-05-08
MEDI SVP, Chief Financial Officer 178 $33.38 $5.9K -$46.2K 3 2007-06-19

Recent Filings · Page 2 of 7

66 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-05-22 INO Grant (A) $0 EDGAR
2024-05-16 INO Exer (M) +2,166 $0 EDGAR
2024-03-25 ENGNW Grant (A) $0 EDGAR
2024-02-05 89bio, Inc. (ETNB) Delisted Grant (A) $0 EDGAR
2023-06-05 INO Notice (144) −5,700 -$3.2K EDGAR
2023-06-05 INO Sell (S) −5,700 -$3.2K EDGAR
2023-05-16 INO Mixed +19,000 $0 EDGAR
2023-05-12 LUMOS PHARMA, INC. (LUMO) Delisted Grant (A) $0 EDGAR
2023-02-13 89bio, Inc. (ETNB) Delisted Grant (A) $0 EDGAR
2022-12-23 ZYME Grant (A) $0 EDGAR
Showing 1120 of 66
Page 2 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.